Evidence map›Paper›PMID 39856266›Full record

ArticleCerebellum (London, England)2025

Assessment of Peripheral Neuropathy Using Current Perception Threshold Measurement in Patients with Spinocerebellar Ataxia Type 3.

Xia-Hua Liu, Wei Lin, Hao-Ling Xu, Mao-Lin Cui, Zhuo-Ying Huang, Ying Li, Nan-Nan Zhang, Ning Wang, Zhi-Yong Wang, Shi-Rui Gan and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Cerebellum (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Xia-Hua LiuDepartment of Rehabilitation Medicine, The First Affiliated Hospital, Fujian Medical University, 20 Chazhong Road, Fuzhou, China.
Wei LinDepartment of Neurology, Fujian Key Laboratory of Molecular Neurology, Fujian Institute of Neurology, The First Affiliated Hospital, Fujian Medical University, Key Laboratory of Brain Aging and Neurodegenerative Diseases of Fujian Medical University, 20 Chazhong Road, Fuzhou, 350005, China.
Hao-Ling XuFujian Key Laboratory of Molecular Neurology, Institute of Clinical Neurology, Institute of Neuroscience, Fujian Medical University, Fuzhou, China.
Mao-Lin CuiSchool of Special Education and Rehabilitation, Binzhou Medical University, Yantai, 264003, People's Republic of China.
Zhuo-Ying HuangDepartment of Neurology, Fujian Key Laboratory of Molecular Neurology, Fujian Institute of Neurology, The First Affiliated Hospital, Fujian Medical University, Key Laboratory of Brain Aging and Neurodegenerative Diseases of Fujian Medical University, 20 Chazhong Road, Fuzhou, 350005, China.
Ying LiClinical Oncology School of Fujian Medical University, Fujian Cancer Hospital (Fujian Branch of Fudan University Shanghai Cancer Center), Fuzhou, China.
Nan-Nan ZhangDepartment of Rehabilitation Medicine, The First Affiliated Hospital, Fujian Medical University, 20 Chazhong Road, Fuzhou, China.
Ning WangDepartment of Neurology, Fujian Key Laboratory of Molecular Neurology, Fujian Institute of Neurology, The First Affiliated Hospital, Fujian Medical University, Key Laboratory of Brain Aging and Neurodegenerative Diseases of Fujian Medical University, 20 Chazhong Road, Fuzhou, 350005, China. ningwang@fjmu.edu.cn.
Zhi-Yong WangDepartment of Rehabilitation Medicine, The First Affiliated Hospital, Fujian Medical University, 20 Chazhong Road, Fuzhou, China. fjykdxwzy@163.com.
Shi-Rui GanDepartment of Neurology, Fujian Key Laboratory of Molecular Neurology, Fujian Institute of Neurology, The First Affiliated Hospital, Fujian Medical University, Key Laboratory of Brain Aging and Neurodegenerative Diseases of Fujian Medical University, 20 Chazhong Road, Fuzhou, 350005, China. ganshirui@fjmu.edu.cn.
OSCCAR Investigators

Funding

Foundation for Innovative Research Groups of the National Natural Science Foundation of China 82230039the Joint Funds for the Innovation of Science and Technology of Fujian Province the Joint Funds for the Innovation of Science and Technology of Fujian Provincethe Local Science and Technology Development Project guided by the central government grants 2022L3011the Natural Science Fundation of Fujian Province 2023J01603
6 · The paper itself

Abstract

Peripheral neuropathy (PN) identified as a significant contributor to disability in Spinocerebellar ataxia type 3 (SCA3) patients. This study seeks to assess the utility of current perception threshold (CPT) measurements in evaluating PN in individuals with SCA3 and aims to identify factors influencing CPT values in SCA3 and ascertain whether these values correlate with the severity of ataxia. Ninety-four patients diagnosed with SCA3 and 44 healthy controls were recruited for this investigation. All participants were performed standard CPT assessments. Comparative analysis was conducted on CPT variables between the groups. Multivariable linear regression models were employed to identify potential risk factors influencing CPT values, and to investigate the association between CPT values and the severity of ataxia in SCA3. The case group exhibited significantly higher values across all CPT variables compared to the control group (P < 0.01). Peripheral neuropathy was prevalent among SCA3 patients, with lower limb nerves demonstrating greater susceptibility than upper limb nerves. Increasing age (β = 1.813, P = 0.012) and heightened ataxia severity (β = 3.763, P = 0.013) as predictors of poorer CPT values. Gender also emerged as a predictor of CPT values. Furthermore, CPT values (β = 0.003, P = 0.013) and disease duration (β = 0.118, P < 0.001) were associated with more severe ataxia. Our findings suggest that the CPT test holds promise for assessing peripheral neuropathy in SCA3 patients and that CPT values may serve as indicators of disease severity in this population.

Indexed as

Machado-Joseph DiseasePerceptionPeripheral Nervous System DiseasesSensory ThresholdsAdultAgedFemaleHumansMaleMiddle AgedSeverity of Illness IndexYoung AdultCurrent perception thresholdPeripheral neuropathySpinocerebellar ataxia type 3

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.